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Abstract 10 
The placebo effect is widely recognized, but important questions remain, for 11 
example whether the capacity to respond to a placebo is an evolved, and potentially 12 
ubiquitous trait, or an unpredictable side-effect of another evolved process. 13 
Understanding this will determine the degree to which the physiology underlying 14 
placebo effects might be manipulated or harnessed to optimize medical treatments. 15 
We argue that placebo effects are cases of phenotypic plasticity where once 16 
predictable cues are now unpredictable. Importantly, this explains why placebo-like 17 
effects are observed in less complex organisms such as worms and flies. Further, this 18 
indicates that such species present significant opportunities to test hypotheses that 19 
would be ethically or pragmatically impossible in humans. This paradigm also 20 
suggests that data informative of human placebo effects pre-exists in studies of 21 
model organisms.  22 
 23 
Keywords: Caenorhabditis; Drosophila; nocebo effect; phenotypic plasticity, placebo 24 
effect.  25 
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The non-living environment does not lie. What you see, feel or smell is what you get. 26 
It therefore pays to behave, develop and respond appropriately. If it’s raining then 27 
use an umbrella, and if you know what the future has in store – perhaps because you 28 
can see nothing but black clouds – then you should prepare accordingly and take 29 
your umbrella. The key is the predictability; if a cue can be used to accurately assess 30 
what the future holds then responding appropriately is the best strategy. Predictable 31 
cues make it possible for organisms to evolve ways to modify their biology to 32 
maximize fitness. We see this in various types of phenotypic plasticity where single 33 
genotypes produce, via changes in development or physiology, different phenotypes 34 
in response to the environment (1). Such responses range from short-term 35 
modifications of physiology to trans-generational effects that persist for many 36 
generations.  37 
 38 
The key difference between a direct response to the environment and phenotypic 39 
plasticity is that the latter relies on the detection of a cue. Hence, an organism’s 40 
response to food might be a direct response to glucose in the bloodstream or an 41 
indirect, and phenotypically plastic, response arising from the smell of food. 42 
Phenotypic plasticity is ubiquitous. Organisms that are not responsive to 43 
environmental conditions were long ago out-competed by mutants that can 44 
accurately tailor their biology to the conditions they will experience. This ubiquity 45 
also suggests that phenotypic plasticity is evolutionarily ancient, and hence for 46 
metazoans will be grounded in the basics of the nervous and endocrine systems that 47 
control and regulate life.  48 
 49 
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Placebo effects, real responses to false cues, potentially stand at odds with the view 50 
that, for adaptive reasons, organisms respond only to true environmental cues. In 51 
placebo effects, phenotypic responses are seen in the absence of a biologically active 52 
agent. Most frequently associated with placebo control conditions in clinical trials of 53 
drugs, placebo effects actually represent a broader class of responses. Hence, 54 
‘placebo’, ‘placebo control’ and ‘placebo effect’ refer respectively to sham/dummy 55 
treatments, a control process for a set of experimental artifacts, and legitimate 56 
neurophysiological events. Here we argue that what we currently recognize as the 57 
placebo effect is the result of humans as a species changing our environment such 58 
that cues that once accurately predicted the future environment no longer do so, i.e. 59 
we have made the environment lie. Placebo effects are not therefore artifacts or 60 
anomalies, but rather are examples of phenotypic plasticity that evolved to respond 61 
to what were once predictable cues in our environment.  62 
 63 
Placebo effects result from a broad range of environmental stimuli that goes beyond 64 
traditional ideas of sham tablets only. In fact, the range of information that can 65 
influence the response to a sham treatment is broad and includes many 66 
environmental and psychosocial variables, such as verbally communicated 67 
expectations of an effect, previous experience of an effect (learning), manipulated 68 
learning (conditioning), context such as the ‘white coat effect’, and emotional 69 
responses such as hope and anxiety. All are manifest in responses via a number of 70 
discrete biological processes, including dopamine (2), opioid (3), and cannabinoid (4) 71 
pathways, with similar pathways often observed for both placebo effects and the 72 
drug they are mimicking (2, 5).  This has collectively been described as “the new 73 
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physiology of the doctor-patient relationship” (6). This emergent viewpoint is 74 
shifting thinking around the placebo effect away from vague self-reported and 75 
subjective responses towards robust and directly measured biological events.  76 
 77 
Arguably, if the placebo effect is biologically real in humans, it evolved for a purpose. 78 
An evolutionary case can be made for a response that can reduce the severity of 79 
subjective symptoms, thereby allowing the organism to better cope with survival-80 
relevant situations. For example, if pain is tolerated for longer it might allow an 81 
individual to produce greater muscle force and therefore running speed and/or 82 
physical strength to capture prey or avoid predation, both potentially life-critical 83 
contexts.  84 
 85 
However, whilst anecdote abounds, it is rare that placebo effects are reliably 86 
observed in any contemporary life-critical context in humans (although the ethical 87 
constraints of administering experimental placebo treatments in such contexts must 88 
be acknowledged). This appears slightly at odds with the idea that traits closely 89 
linked to fitness are likely to be the most responsive to environmental variation. This 90 
presents a paradox; if placebo effects occurred only in relation to subjective 91 
symptoms, no matter how unpleasant to the individual (e.g. pain, fatigue and 92 
depression), it is doubtful they would have been sufficiently responsive to natural 93 
selection for the placebo effect to earn its place in contemporary human biology. 94 
 95 
There are exceptions. For example, Benedetti and co-workers (7) reported the 96 
effects of sham oxygen on pain, fatigue and performance among subjects 97 
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experiencing chronic exposure to severe hypoxia at 3,500m of altitude. Whilst the 98 
main outcome variable of the study was hypoxia induced pain, the ability of subjects 99 
to produce physical work at reduced perception of fatigue suggests that even life-100 
critical functions such as oxygen supply are placebo responsive.  101 
 102 
Another interesting exception is Parkinson’s disease (PD), which although not life 103 
critical per se, reduces lifespan in the majority of patients. In fact, examining the 104 
table of contents of books on placebo effects, PD stands out from the list of 105 
otherwise ostensibly subjective conditions like the proverbial sore thumb.  106 
 107 
The role of dopamine in PD has long been recognized. Increasingly the role of the 108 
same neurotransmitter is recognized in placebo responses in many scenarios. 109 
Benedetti and co-workers analysed the effects of a placebo in PD patients, 110 
specifically the effects on dopamine release in the striatum and the modification of 111 
neuronal activity in both the thalamus and subthalamic nuclei. In naïve patients, a 112 
first placebo administration resulted in no change in neural or clinical measures. 113 
However, in patients previously administered the anti-Parkinson’s drug 114 
apomorphine, the number of repeated exposures to apomorphine predicted both 115 
the neural and clinical responses of patients to placebos. Critically, these effects 116 
were of the same magnitude as those elicited by the drug itself, suggesting a 117 
significant role for learning in the placebo response observed (2).  118 
 119 
Placebo responses have also been observed in response to nutritional treatment 120 
that were presented, but not actually ingested (8). For example, athletes who were 121 
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not glucose deficient show performance increases when glucose is introduced to the 122 
mouth and then withdrawn without being ingested, this ‘glucose rinsing’ also 123 
resulting in clear neurophysiological responses. An analogous effect has been 124 
observed with caffeine rinsing (9) These placebo effects can be understood in terms 125 
of the body responding to a predictable cue – detecting glucose or caffeine in the 126 
mouth normally indicates that it will soon be available in the intestine – by altering 127 
resource allocation.  128 
 129 
If placebo responses seen in humans are the result of phenotypic plasticity, then 130 
placebo-like effects should be observable in other species – particularly in cases 131 
where the environment has been altered to disrupt its reliability. This is the case, 132 
and placebo-like effects are seen in a variety of model systems. Importantly, these 133 
examples are directly linked to fitness and rely on widely conserved signaling 134 
pathways. 135 
 136 
Although addressing placebo effects per se, Ader & Cohen (10) reported the 137 
conditioned immunosuppression of rats, a study that whilst Sokolowsa et al (11) 138 
demonstrated how a ‘probe dose’ of 10% of the normal dose of morphine triggered 139 
morphine like effects, again in rates.  However, placebo effects have to date been 140 
largely studies in humans, and when not in humans, in vertebrates. Little or no work 141 
to date has examined the possibility of placebo effects in simple invertebrate model 142 
organisms. However, it is plausible that such species experience similar responses.  143 
 144 
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In situations analogous to those seen in human experiments above, the perception 145 
of food matters in model organisms. A widespread means of extending lifespan is to 146 
reduce the overall calorific intake whilst preserving vitamin/mineral needs and 147 
avoiding starvation (12). This lifespan extending response to calorific or dietary 148 
restriction (DR) is seen widely in eukaryotes, and represents potentially the most 149 
viable non-pharmacological means of extending human life and health-span (13). In 150 
the nematode worm Caenorhabditis elegans and the fruit fly Drosophila 151 
melanogaster, DR via a range of methods extends lifespan, with lifespan extensions 152 
of up to 50% observed in C. elegans. The regulation of the DR response is complex, 153 
but work in many systems demonstrates the involvement of insulin-like signaling and 154 
the highly-conserved mTOR (mechanistic target of rapamycin) pathway (14). The life-155 
extending effects of DR can however be blocked in both worms and flies by the smell 156 
of food alone (15, 16). Hence in situations where there is a mismatch between 157 
perception and reality, the standard DR response is not seen. In these cases, the 158 
smell of food is therefore acting as a placebo, or more correctly what is termed a 159 
‘nocebo’, a negative placebo response resulting in no lifespan extension.  160 
 161 
Likewise, work on C. elegans shows that the neuronal perception of cold, rather than 162 
the system-wide effects of temperature on cellular function per se, are critical for 163 
cold stress survival. Low temperatures damage C. elegans and can kill them, with 164 
adult worms dying if they are exposed to temperatures lower than 5°C for prolonged 165 
periods (17, 18). This mortality can be greatly reduced, or even blocked, by 166 
habituation – worms exposed to low, but non-stressful, temperatures are then 167 
highly resistant to subsequent acute cold stress (17, 18). Critically, this habituation is 168 
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a result of worm’s perception of temperature as opposed to the environmental 169 
reality, as disruption of specific neurons can replicate the habituation response in 170 
the absence of any temperature change (18, 19). The response, in this case the 171 
survival or not of a subsequent stress, is therefore based not on the temperature 172 
itself, but on the perception of temperature. This perception of temperature then 173 
feeds into the insulin-like signaling pathway (18, 20), one of the core highly-174 
conserved pathways that regulates nutrient allocation and lifespan in eukaryotes. 175 
  176 
Hence, in both worms and flies we can observe placebo effects; there is an 177 
expectation of something and a subsequent set of changes that (should) optimize 178 
fitness under the expected condition. Critically though, the trigger is neuronal and 179 
hence can be separated from the actual environment that is being perceived or 180 
expected. The reality of environmental temperature is less positive than the signal, 181 
and it is the signal to which the organism responds; temperature sensation in a light 182 
and pheromone-sensing neuron produces a robust effect on insulin signalling that 183 
controls experience-dependent temperature habituation. Likewise, the reality of 184 
reduced caloric intake is less critical to survival than the perception, suggesting a 185 
calorie-independent mechanism for life span extension by caloric restriction. 186 
 187 
It is increasingly clear that the biology underpinning the placebo effect in humans 188 
could have significant clinical and societal impacts. One reasons that we know so 189 
much about the neurophysiological response to placebo treatments among PD 190 
patients is that we are able to conduct research on real-time neuronal activity by 191 
using the electrodes implanted for the treatment of the disease itself, deep brain 192 
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stimulation. PD might not be, as is suggested above, an exception, it might simply be 193 
the medical condition in humans in which it has been easiest to secure relevant data. 194 
In PD therefore, the response to placebos is less a problem for clinical trials and/or a 195 
unique opportunity for placebo effect researchers, but a potential clue to future 196 
treatments. Far from controlling for the placebo effect in clinical trials, scientists 197 
should in fact be seeking to understand and harness the biological processes that in 198 
many cases constitute to a substantial percentage of the overall effectiveness of the 199 
drug when compared to no-treatment. In short, this field of study could become 200 
important and impactful. 201 
 202 
However, the study of placebo responding in humans is plagued by ethical, logistical 203 
and cost issues. Scenarios such as PD in which conventional medical treatment 204 
facilitates easy and reliable access to brain activity are rare. There are many 205 
questions that might be asked in humans with relative ease, for example we should 206 
be able to answer the question of whether all individuals respond similarly to non-207 
ingested glucose mouthwash, arguably a direct neuronal prediction. But these are 208 
not the critical questions; placebo responses that require a cognitive prediction are 209 
more problematic to study.  For example, those effects that result from anticipation 210 
or expectation of an effect, that might be moderated by a number of affective and 211 
cognitive factors such as environmental cues, emotion, memory, sensation and 212 
perception.     213 
 214 
That placebo responses might be open to study and to systematic manipulation in 215 
simple model organisms could significantly enhance our understanding of the 216 
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response in humans. We therefore propose five hypotheses that could be tested in 217 
animal models: 1) Placebo-like effects are ubiquitous responses to a set of 218 
standardized environmental cues across organisms (i.e., we would expect to see 219 
placebo effects to a similar type of cue across numerous organisms); 2) Placebo-like 220 
responses will be limited to certain types of species-relevant environmental 221 
information such as temperature and energy availability (i.e., we would expect to 222 
see evolved responses in life-critical contexts); 3) The capacity to respond to a novel 223 
placebo-like cue can be acquired through evolution within a species and/or learning 224 
within an organism; 4) A threshold magnitude of information (e.g., temperature, 225 
energy availability) is required to elicit a placebo-like effect (this threshold likely 226 
related to the significance of the information in critical survival terms); and 5) The 227 
threshold magnitude for a placebo-like cue can be experimentally modified to 228 
enhance the dose-response relationship. Several of the above questions might be 229 
addressed by experimental evolution in model systems which should be able to test 230 
the levels of predictability required to maintain and modify responses. Critically, this 231 
paradigm also suggests that a wealth of data informative of human placebo effects 232 
already exists in studies of model organisms, and several of the hypotheses might be 233 
amenable to secondary analysis.    234 
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